Premium
Review article: topical corticosteroids in inflammatory bowel disease
Author(s) -
MULDER C. J. J.,
TYTGAT G. N. J.
Publication year - 1993
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1993.tb00080.x
Subject(s) - medicine , corticosteroid , inflammatory bowel disease , budesonide , prednisolone , fluticasone propionate , betamethasone , dermatology , gastroenterology , pharmacology , disease
SUMMARY It would be ideal to treat inflammatory bowel disease with topical corticosteroids that are either not absorbed through the mucosa, or have a substantial first‐pass hepatic metabolism. The topical use of hydrocortisone, prednisolone‐21‐phosphate or betamethasone is often associated with systemic side‐effects. Newer corticosteroid preparations (prednisolone metasulphobenzoate, tixocortol pivalate, fluticasone propionate, beclomethasone dipropionate and budesonide) are usually associated with minimal systemic corticosteroid activity. This article reviews the clinical activity and safety of these newer preparations.